Gafter-Gvili Anat, Ribakovsky Elena, Mizrahi Nadav, Avigdor Abraham, Aviv Ariel, Vidal Liat, Ram Ron, Perry Chava, Avivi Irit, Kedmi Meirav, Nagler Arnon, Raanani Pia, Gurion Ronit
a Institute of Hematology, Davidoff Cancer Center, Rabin Medical Center , Petah-Tikva , Israel.
b Sackler School of Medicine , Tel-Aviv , Israel.
Leuk Lymphoma. 2016;57(1):63-9. doi: 10.3109/10428194.2015.1046862. Epub 2015 May 25.
A multi-center retrospective analysis of a cohort of patients in Israel treated with any bendamustine containing regimen between 2010-2014 was performed in order to determine the incidence and predictors for infection. The Kaplan Meier Model, employing log rank analysis, was used to assess time-to-infection. The Cox Proportional Hazards model was used to analyze multivariate effects of risk and 234 patients were included in the analysis. One hundred and nine (46.6%) developed at least one infection and 33.76% had severe infections. Seventy-six (41.5%) developed bacterial infection, nine (3.8%) fungal infection and 26 (11.5%) had viral infections. Factors significantly associated with time to infection on multivariable analysis were: bendamustine-combinations [hazard ratio (HR) = 0.589 (95% CI = 0.374-0.926), p = 0.022], Hb level [HR = 0.791 (95% CI = 0.716-0.875), p < 0.0001] and ischemic heart disease [HR = 1.828 (95% CI = 1.165-2.868), p = 0.009]. Infections were associated with a higher mortality and hospitalization rate.
为了确定感染的发生率和预测因素，对2010年至2014年期间在以色列接受任何含苯达莫司汀治疗方案的一组患者进行了多中心回顾性分析。采用对数秩分析的Kaplan Meier模型用于评估感染时间。Cox比例风险模型用于分析风险的多变量效应，共有234例患者纳入分析。109例（46.6%）发生至少一次感染，33.76%发生严重感染。76例（41.5%）发生细菌感染，9例（3.8%）发生真菌感染，26例（11.5%）发生病毒感染。多变量分析中与感染时间显著相关的因素有：苯达莫司汀联合用药[风险比（HR）=0.589（95%置信区间=0.374-0.926），p=0.022]、血红蛋白水平[HR=0.791（95%置信区间=0.716-0.875），p<0.0001]和缺血性心脏病[HR=1.828（95%置信区间=1.165-2.868），p=0.009]。感染与较高的死亡率和住院率相关。
